Telix Pharmaceuticals and CellSight Technologies Conclude Collaboration and License Agreement for VisAcT ImmunoPET Technology
(WorldNews Health)

MELBOURNE, Australia and SAN FRANCISCO, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, the Company) is pleased to announce the conclusion of a collaboration and licensing agreement with CellSight Technologies, Inc. (CellSight) for the VisAcT immunoPET imaging technology (VisAcT). The VisAcT technology enables visualization of the localization and migration of immune cells using Positron Emission Tomography (PET), an important imaging modality in the management of cancer. ......